Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease
Authors
Keywords
Lipoprotein(a), PCSK9 inhibitors, Niacin, Statins, CETP inhibitors
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 30, Issue 1, Pages 101-108
Publisher
Springer Nature
Online
2016-02-09
DOI
10.1007/s10557-016-6654-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients
- (2016) Stephen J. Nicholls et al. Journal of Clinical Lipidology
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance
- (2015) Raul D. Santos et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
- (2014) John J. P. Kastelein et al. CARDIOVASCULAR DRUGS AND THERAPY
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
- (2014) Barbara Sjouke et al. Lancet Diabetes & Endocrinology
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- Estrogens and cardiovascular disease risk revisited
- (2013) Barbara V. Howard et al. CURRENT OPINION IN LIPIDOLOGY
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Antisense oligonucleotides for the treatment of dyslipidaemia
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
- (2012) Gregory C. Shearer et al. JOURNAL OF LIPID RESEARCH
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Lipoprotein(a) metabolism: Potential sites for therapeutic targets
- (2012) Jane Hoover-Plow et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects
- (2011) Salim S. Virani et al. CIRCULATION
- Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance
- (2011) E. Moutzouri et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia
- (2011) Tsuyoshi Nozue et al. Journal of Atherosclerosis and Thrombosis
- Farnesoid X receptor represses hepatic human APOA gene expression
- (2011) Indumathi Chennamsetty et al. JOURNAL OF CLINICAL INVESTIGATION
- Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
- (2010) Kåre Berg et al. CLINICAL GENETICS
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
- (2010) Paul W. Ladenson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy criteria and cholesterol targets for LDL apheresis
- (2009) Gilbert R. Thompson et al. ATHEROSCLEROSIS
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
- (2008) Frederick F Samaha et al. Nature clinical practice. Cardiovascular medicine
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started